Share this:

November 29th, 2014 · Leave a Comment

Uniting the Global Stem Cell Community

By Center for Regenerative Medicine

wscs14logo-16by9

Mayo Clinic Center for Regenerative Medicine to Co-Host the World Stem Cell Summit in San Antonio

The World Stem Cell Summit, December 3-5 in San Antonio, unites and educates the global stem cell community. With more than 1,200 attendees from more than 40 countries, the annual World Stem Cell Summit’s interdisciplinary agenda explores disease updates, research directions, cell standardization, regulatory pathways, reimbursements, financing, venture capital and economic development.

Throughout the week, the Mayo Clinic Center for Regenerative Medicine will use social media to connect using the hashtag #WSCS14. At the end of the week, we'll let the tweets, Google+ posts, Flickr photos, Facebook posts and YouTube videos tell the story.

The World Stem Cell Summit includes in-depth programming and more than 200 international speakers, including leaders from the Mayo Clinic Center for Regenerative Medicine:

  • Atta Behfar, M.D., Ph.D., is director of the Cardiac Regeneration Program in the Mayo Clinic Center for Regenerative Medicine. Dr. Behfar and colleagues are working on new science and clinical trials in heart disease that harness the reparative capacity of a patient’s own stem cells.
  • Jeffrey Janus, M.D. is assistant professor in Otolaryngology, Head & Neck Surgery at Mayo Clinic in Rochester, Minn. He specializes in head & neck oncologic and reconstructive surgery. Dr. Janus's research endeavors primarily focus on craniofacial bone restoration and stem cell solutions for radiation damage.
  • Timothy Nelson, M.D., Ph.D., is director of the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome(HLHS). In the program, Mayo Clinic physicians and researchers are working to launch clinical trials that bring the latest advances in cell therapy to people with HLHS. Additionally, Dr. Nelson oversees the Regenerative Medicine Consult Service at Mayo Clinic, which provides educational information and appropriate referrals to patients who want to learn about regenerative medicine opportunities at Mayo Clinic and elsewhere.
  • Zachary Resch, Ph.D., is assistant professor of medicine and program manager for the Center for Regenerative Medicine Biotrust at Mayo Clinic. The Biotrust is specializes in the collection, processing, and storage of human biomaterials for regenerative medicine applications.
  • Shane Shapiro, M.D., is a consultant in the Department of Orthopedic Surgery at Mayo Clinic and is an instructor of Family Medicine at Mayo Clinic College of Medicine. A primary focus of his research has been the study of novel regenerative techniques for chronic non-healing bone, joint, muscle, tendon, ligament and skin maladies that are not candidates for conventional surgical management. Most recently, the FDA has granted Dr. Shapiro an investigational new drug (IND) to study the use of autologous enriched bone marrow aspirate for use in osteoarthritic knees.
  • Nathan Staff, M.D., a neurologist clinician-investigator, uses neuroregenerative strategies in both laboratory-based model systems and human clinical trials to study disorders that damage the peripheral nervous system. His research focuses on chemotherapy-induced peripheral neuropathy (CIPN) and amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease).  He has been one of the leaders of Mayo Clinic’s Phase I Clinical Safety Trial studying injection of autologous mesenchymal stem cells in patients with ALS.
  • Andre Terzic, M.D., Ph.D., is the Michael S. and Mary Sue Shannon Director, Mayo Clinic Center for Regenerative Medicine and Marriott Family Professor in Cardiovascular Diseases Research. Dr. Terzic has pioneered regenerative medicine at Mayo Clinic, and his program capitalizes on emerging technologies to transform therapeutic modalities from palliative measures to cures.
  • Anthony Windebank, M.D., a neurologist and molecular biologist, is deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine. He is director of the Cellular Neurobiology Laboratory, which focuses on repair and regeneration after spinal cord injury, repair and regeneration of peripheral nerve and stem cell applications for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
  • Michael Yaszemski, M.D., Ph.D., is a Mayo Clinic orthopedic surgeon, biomedical engineer, and co-director for both bone regeneration and nerve injury research at Armed Forces Institute of Regenerative Medicine. He will participate in a session on the United States military investment in Regenerative Medicine session.
  • Abba Zubair, M.D., Ph.D., is a consultant in the Department of Laboratory Medicine and Pathology and medical director, Transfusion Medicine and Stem Cell Therapy at Mayo Clinic in Jacksonville, Fla. Dr. Zubair’s research focuses on the use of stem cells for regenerative medicine applications. He recently received an award from NASA (CASIS) that will allow him to use the microgravity environment to grow stem cells that are of sufficient quality and quantity to use in the treatment of patients with stroke.

About the World Stem Cell Summit
Mayo Clinic, The University of Texas Health Science Center at San Antonio, Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS), BioBridge Global, Baylor College of Medicine and the Regenerative Medicine Foundation have joined the Genetics Policy Institute to organize the 10th Annual World Stem Cell Summit — the largest and most comprehensive multi-track interdisciplinary stem cell conference.

Related Links
Mayo Clinic at World Stem Cell Summit 2013
Mayo Clinic at World Stem Cell Summit 2012

 

View full entry · Comment on this

Tags: Andre Terzic, Mayo Clinic, Regenerative Medicine, Research, stem cells, World Stem Cell Summit, WSCS, WSCS14


November 19th, 2014 · Leave a Comment

Mayo Scientist Receives American Heart Association 2014 Basic Research Prize

By Center for Regenerative Medicine

The AmATerican Heart Association (AHA) awarded the 2014 Basic Research Prize to Andre Terzic, M.D., Ph.D., of Mayo Clinic. The award, presented at the annual meeting of the American Heart Association in Chicago, recognizes outstanding contributions to the advancement of cardiovascular science. Dr. Terzic was commended for pioneering applications of emerging technologies to advance the diagnosis and treatment of cardiovascular diseases.

“In the year when we celebrate the 100th anniversary of the Division of Cardiovascular Diseases at Mayo Clinic, we are particularly proud that one of our own has been recognized with such a prestigious national award,” says Charanjit Rihal, M.D., chair of Mayo's Division of Cardiovascular Diseases. “Dr. Terzic has truly advanced the frontiers of medical science. As a pioneer in cardiac regenerative medicine, he and his team have been at the vanguard of health care.”

“As we look into the future, the pandemic of cardiovascular disease will mandate new solutions, indeed disruptive innovations, to address the unmet needs of patients and populations across the globe,” Dr. Terzic said when he accepted the prize. “The unison of fundamental discovery with clinical translation — and ultimately application to populations — will provide a guiding principle for generations to come.”

View full entry · Comment on this

Tags: American Heart Association, Andre Terzic, Cardiology, Heart Disease, Mayo Clinic, Minnesota news release, Regenerative Medicine, stem cells


October 27th, 2014 · Leave a Comment

Meet the Researchers – Drs. Anthony Windebank and Nathan Staff Discuss ALS Research at Mayo Clinic

By Center for Regenerative Medicine

Anthony Windebank, M.D., and Nathan Staff, M.D., Ph.D., presented “ALS and Mayo Clinic – A Long History of Partnership in Research and Care” during Mayo Clinic Heritage Days in Rochester, Minn.

Dr. Windebank, professor of neurology and deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine, and Dr. Staff, assistant professor of neurology, are studying the use of mesenchymal stem cells derived from patient adipose (fat) tissue delivered to the spinal fluid of patients with amyotrophic lateral sclerosis (ALS). ALS is often called Lou Gehrig’s disease, after Lou Gehrig, a hall-of-fame baseball player for the New York Yankees who was diagnosed with ALS at Mayo Clinic in 1939.

Watch the presentation, filmed at the Mayo Clinic Research Information Center, below:

More information:
New Hope: Stem Cell Trial for ALS Patients

View full entry · Comment on this


October 15th, 2014 · Leave a Comment

Collaboration Highlight: Cardio3 BioSciences

By Center for Regenerative Medicine

Since 2007, Mayo Clinic and Cardio3 BioSciences, a biotechnology company based in Mont-Saint-Guibert, Belgium, have collaborated to advance our knowledge of disease in order to provide new solutions for patients and innovative delivery of quality care in the area of cardiac regeneration. Cardiac regenerative medicine uses reparative tools to restore damaged tissue and restitute function caused by heart disease.

Cardio3 BioSciences has successfully developed Mayo Clinic innovation leading to completion of a phase II trial on cardiopoetic stem cells in patients with heart failure. The Food and Drug Administration (FDA) has recently cleared the way for the Belgian company and Mayo Clinic to launch a phase III clinical trial of its stem cell therapy based on Mayo Clinic regenerative medicine research later this year.

Clinical application of regenerative biologics has emerged as a next generation tool that can be tailored to augment existing therapeutic strategies for otherwise incurable diseases, including heart failure. By leveraging research collaborations, such as with Cardio3 BioSciences, Mayo Clinic is positioned to transform the way we treat patients with heart disease.

Clinical Trials

3251267-001[1]In collaboration with Cardio3 BioSciences, Mayo Clinic researchers have discovered a novel way to repair a damaged heart by regenerating heart tissue.

In Mayo Clinic's breakthrough process, stem cells are harvested from a patient's bone marrow. The stem cells undergo a laboratory treatment that guides them into becoming cardiac cells. The treated cells are then injected into the patient's heart in an effort to grow healthy heart tissue.

“In regenerative medicine, the step between lab tests and clinical trials is a big one and the interaction with Cardio3 is crucial to driving Mayo Clinic's technology forward," says Atta Behfar, M.D., Ph.D., who spent several months in Belgium working with Cardio3 BioSciences. Dr. Behfar, a heart failure and transplant specialist, leads the Cardiac Program in the Mayo Clinic Center for Regenerative Medicine.

Atta Behfar, M.D., Ph.D.

Atta Behfar, M.D., Ph.D.

Product Development

In late 2013, Mayo Clinic researchers and Cardio3 BioSciences developed a specialized catheter for transplanting stem cells into the beating heart. The novel cardiac catheter is able to dramatically improve stem cell retention in the heart. The device includes a curved needle and graded openings along the needle shaft, allowing for increased distribution of cells. The result is maximized retention of stem cells to repair the heart. The findings appear in the journal Circulation: Cardiovascular Interventions.

This new catheter is being used in the European CHART-1 clinical trials, now underway. This is the first Phase III trial to regenerate hearts of patients who have suffered heart attack damage. The studies are the outcome of years of basic science research at Mayo Clinic and earlier clinical studies with Cardio3 BioSciences and Cardiovascular Centre in Aalst, Belgium.

Clark Otley, M.D.

Clark Otley, M.D.

Preferred Access Agreement

Most recently, Mayo Clinic and Cardio3 BioSciences entered into an extended collaboration agreement.  It builds on a long established and productive relationship of licensing and research in the area of cardiac regeneration.  The mutual hope for this work is that together Mayo and Cardio3 BioSciences can accelerate Mayo discoveries toward clinical application.

Under the Preferred Access Agreement, the parties have agreed to regular periodic meetings to review Mayo’s regenerative medicine portfolio to identify areas and projects of mutual interest.   The results of these conversations could potentially lead to cooperative research projects, license agreements or introductions to third parties to further the technology.

“We are excited for the opportunity to expand our collaboration with Cardio 3 and accelerate the delivery of novel therapies to patients”, says Clark Otley, M.D., Medical Director of Mayo Clinic Ventures which works to commercialize Mayo Clinic technologies for the benefit of patients worldwide.

The Center for Regenerative Medicine continues to explore strategic relationships with academic, biotechnology/industry, government and professional associations at the local, regional, national and international level.

For more information, visit the Mayo Clinic Center for Regenerative website or email RegenMed@mayo.edu.

View full entry · Comment on this


October 13th, 2014 · Leave a Comment

Register for “HLHS: Feel the Beat”

By Center for Regenerative Medicine

HLHS“Feel the Beat” is an annual event that highlights Mayo Clinic’s commitment to transforming the practice of congenital heart disease with innovative regenerative strategies to prevent heart failure due to structural heart disease. This event brings together physicians, scientist, and children and families affected by severe heart defects, such as Hypoplastic Left Heart Syndrome (HLHS).

The Todd and Karen Wanek Family Program for HLHS is honored to host this event with some notable guests this year. Team members will showcase the latest research, guest speakers will share inspiring stories, and the congenital heart disease community will come together.

HLHS Feel the Beat” will be held Saturday, Nov. 8 at Mayo Clinic in Rochester, Minn. For more information, visit the "HLHS: Cause to Cure" blog.

View full entry · Comment on this


See all posts →